SOURCE: Active Biotech

February 11, 2010 02:55 ET

Active Biotech AB Year-end Report, January - December 2009

LUND, SWEDEN--(Marketwire - February 11, 2010) -


Laquinimod -- Phase III program proceeding according to plan

57-57 -- exploratory clinical trial in progress

RhuDex™ -- additional preclinical studies to be conducted in 2010

ANYARA -- Phase III trials proceeding according to plan

TASQ -- primary endpoint met in clinical Phase II

ISI -- project proceeding according to plan

Net sales of SEK 10.8 M (53.5)

Operating loss of SEK 219.6 M (loss: 184.6)

Loss after tax of SEK 224.0 M (loss: 181.6)

Loss per share for the period amounted to SEK 3.81 (loss: 3.66)

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00

This report is also available at www.activebiotech.com

Active Biotech AB Year-end Report, January-December 2009: http://hugin.info/1002/R/1383189/341980.pdf

Contact Information